MedCloud Minute
The MedCloud Minute blog is researched, fact-checked, edited and updated by the editors of MedCloudInsider.com, with writing assistance from AI. To submit your company's press release for consideration, contact [email protected].
Pivot Point Consulting, an IT consulting leader in the healthcare sector, has joined the Microsoft Rural Health Resiliency Program, an initiative designed to support rural hospitals and healthcare organizations in strengthening cybersecurity and advancing digital transformation. The collaboration focuses on helping underserved providers adopt secure cloud technologies and modern IT practices. The collaboration will implement Dragon Copilot readiness assessments, provide national webinars and demo, ensure workflow design governance is adhered to and provide education at major rural and digital health conferences. Rural hospitals can request a no-cost Dragon Copilot readiness assessment from Pivot Point Consulting.
Rural healthcare systems often face limited IT resources and heightened cybersecurity risks, particularly as ransomware and phishing attacks increasingly target smaller hospitals. Microsoft’s Rural Health Resiliency Program seeks to address these gaps by combining technology access, security guidance and partner expertise. Through the program, Pivot Point Consulting will provide advisory and implementation services aimed at improving infrastructure resilience, compliance posture and cloud adoption strategies. For healthcare IT leaders, the initiative reflects broader efforts to close the digital divide between urban and rural providers while strengthening cybersecurity defenses across the healthcare ecosystem.
Posted by MedCloudInsider Editors on 03/05/20260 comments
Quest Diagnostics, a leader in diagnostic information services, has introduced an AI-powered companion, called Quest AI Companion, within the MyQuest platform, designed to help patients better understand and act on their lab test results. The tool provides personalized explanations, contextual health information and suggested next steps based on individual diagnostic data, with the goal of improving patient engagement and clarity. Users can prompt the AI Companion to assist with composing questions to ask healthcare providers, empowering patients to have informed conversations with clinicians.
As access to digital health records expands, patients increasingly review lab results directly through online portals, often without immediate clinical interpretation. The AI companion integrates into its digital patient experience, supporting users in understanding results and preparing for follow-up discussions with healthcare providers. For healthcare IT leaders, the launch reflects a broader trend of embedding generative AI into patient-facing platforms to enhance comprehension, streamline communication, and support more informed health decisions.
Posted by MedCloudInsider Editors on 03/03/20260 comments
Aingens, a life sciences software company, has released the findings of a clinical AI reliability test for its platform, MACg (Medical Affairs Content generator), designed to evaluate the performance and safety of AI systems deployed in healthcare environments. The initial results showed zero hallucinations during testing, with 100% accuracy for numerical data, positioning the framework as a benchmark for validating AI accuracy in clinical use cases. The aim of releasing the results is to establish clearer benchmarks and governance standards for AI evaluation and deployment in evidence-critical workflows.
Hallucinations in AI remain a significant concern in healthcare applications, where inaccuracies can carry serious consequences. Aingen's reliability test evaluates AI outputs against verified clinical data and structured medical knowledge to assess consistency and factual accuracy. While broader validation across diverse real-world scenarios will be necessary to confirm long-term performance, the announcement highlights growing emphasis on measurable reliability standards in healthcare AI.
Posted by MedCloudInsider Editors on 03/02/20260 comments
XtalPi, a leading AI and robotics-driven drug discovery platform, announced that its platform has supported a clinical milestone for ReviR Therapeutic's investigational therapy RTX-117, a candidate targeting a rare neurological disorder. The platform helped accelerate key stages of research and development leading up to the clinical advancement. The discovery amplifies how AI-driven precision drug discovery can overcome traditional economic barriers in rare disease R&D. The success of RTX-117 validates the scalability and clinical impact of AI and robotics in expanding treatment options for minority patient groups.
AI-enabled drug discovery platforms are increasingly used to optimize molecular design, predict compound behavior and automate laboratory workflows. Robotics integration allows for high-throughput experimentation and data generation, potentially reducing timelines compared to traditional discovery processes. For life sciences and technology observers, the announcement underscores continued momentum behind AI-enabled drug development models that combine computational prediction with automated laboratory execution.
Posted by MedCloudInsider Editors on 03/02/20260 comments
b.well Connected Health, specialists in digital experiences, has introduced bailey, a ready-to-deploy, white-label AI health assistant designed for healthcare organizations, payers and digital health platforms. bailey can be customized and embedded into existing patient engagement applications, allowing organizations to offer AI-driven guidance under their own brand. Built on the same core infrastructure used by OpenAI and Samsung to power health agents, bailey is built on the b.well Health AI SDK connects data through a 13-step data refinery for a longitudinal health record. bailey offers complete health data integration, agentic AI architecture developed at scale, action-oriented AI, healthcare-grade security, consumer-first privacy and rapid deployment that is white-label ready.
The assistant is built to integrate with clinical and administrative data sources, enabling users to access personalized health information, navigate benefits, and receive support for care coordination. By offering a white-label model, b.well is targeting organizations seeking to maintain brand ownership while adding conversational AI capabilities. For healthcare IT leaders, the launch reflects broader efforts to combine data aggregation platforms with generative AI to create more accessible, patient-centered digital experiences.
Posted by MedCloudInsider Editors on 02/24/20260 comments
Mammotome, a breast cancer treatment company, has launched the Mammotome Prime MR system, described as the first in-room MR vacuum-assisted breast biopsy system, designed to allow clinicians to perform MRI-guided biopsies within the MRI suite. The system enables tissue sampling without requiring patients to be moved to a separate procedure area, aiming to streamline workflow and reduce procedure time. The Mammotome Prime MR system enables a stronger vacuum with larger tissue samples and an 8-gauge needle.
MRI-guided breast biopsy is typically used when lesions are visible only through magnetic resonance imaging. Traditional setups often require additional equipment positioning or patient transfer, which can add complexity to procedures. Advances in vacuum-assisted biopsy systems have focused on improving precision and efficiency while minimizing patient discomfort.
By integrating vacuum-assisted biopsy capabilities directly into the MRI environment, Mammotome is targeting workflow optimization in breast imaging centers. For radiology departments, the development reflects ongoing efforts to improve procedural efficiency and diagnostic accuracy as imaging volumes and demand for minimally invasive interventions continue to grow.
Posted by MedCloudInsider Editors on 02/24/20260 comments
Researchers at the University of Missouri are developing methods to make AI-driven scientific predictions more trustworthy by improving model transparency and reliability. The team is focused on strengthening confidence in machine learning systems used to analyze complex scientific data, particularly in areas where inaccurate predictions could have significant downstream consequences. The database, called PSBench includes 1.4 million annotated protein structure models that give scientists reliable information needed to build AI systems to assess the quality of protein structure models. Previous tools lack the information required to accurately predict every type of protein, but PSBench provides a solution to this marking a significant step in applying protein models to develop treatments.
AI models are increasingly used in scientific research to predict molecular behavior, climate patterns, and biological interactions. However, many of these systems function as “black boxes,” offering limited insight into how conclusions are reached. The Missouri team’s work aims to improve model confidence and create AI predictions that are more reliable. By incorporating validation techniques and explainability tools, the researchers hope to bridge the gap between computational speed and scientific rigor. As AI becomes more embedded in research workflows, ensuring that predictions are both accurate and transparent is emerging as a central priority for the scientific community.
Posted by MedCloudInsider Editors on 02/20/20260 comments
Metabolon, a global leader in metabolomics, announced that its metabolomics platform enabled what the company describes as the largest metabolomic analysis to date in CAR-T cell therapy, generating new insights into severe neurotoxicity associated with the treatment. The study analyzed metabolic profiles from patients undergoing CAR-T therapy and identified distinct metabolite patterns correlated with immune effector cell-associated neurotoxicity syndrome (ICANS), a potentially life-threatening complication. Researchers were able to identify clear, reproducible metabolic signatures that classified patients who developed high-grade NEs using metabolomics to reveal mechanisms that are invisible to genomic, proteomic and cellular assays.
CAR-T therapies have transformed treatment for certain hematologic cancers, but serious side effects such as cytokine release syndrome and neurotoxicity remain significant clinical challenges. By applying high-throughput metabolomics to CAR-T patients, Metabolon’s platform supports more detailed biomarker discovery efforts. For oncology researchers and biopharma developers, the findings underscore how multi-omics approaches are becoming central to managing risk and refining next-generation cell therapies.
Posted by MedCloudInsider Editors on 02/18/20260 comments
Unchained Labs, a life sciences research company, has launched Stuntman, a new AI-driven automation platform designed to help life sciences teams accelerate experimental workflows and reduce reliance on manual laboratory processes. Stuntman combines artificial intelligence, robotics and software orchestration to automate complex, multi-step experiments, allowing scientists to focus more on analysis and discovery rather than routine execution. The integration allows scientists to describe what they aim to do in natural language and have these prompts turn into workflows, help plan experiments, interpret results and guide automation.
Laboratories across biopharma and academic research continue to face pressure to improve productivity amid staffing constraints and rising costs. With Stuntman, Unchained Labs is positioning AI as the connective layer that links instruments, protocols, and data into a unified system. For research organizations, the launch highlights how AI-driven automation is moving from isolated tasks toward holistic lab operations, with the potential to shorten timelines, improve consistency and increase overall research throughput.
Posted by MedCloudInsider Editors on 02/09/20260 comments
MetaVia, a clinical-stage biotechnology company specializing in cardiometabolic diseases, has reported positive results from AI-based modeling conducted as part of its ongoing collaboration with Syntekabio, confirming key therapeutic targets for vanoglipel. The modeling work validated the biological mechanisms underlying the drug candidate, strengthening confidence in its development strategy and supporting continued clinical and preclinical efforts. MetaVia aims to continue leveraging Syntekabio AI to optimize the therapeutic profile of vanoglipel.
The use of AI-driven modeling reflects a broader trend in biopharma, where computational approaches are increasingly applied to de-risk drug discovery and development. For Metavia, the collaboration highlights how AI can complement traditional research methods by providing additional biological insight. More broadly, the results underscore how partnerships between biotech firms and AI specialists are becoming a standard component of modern drug development, particularly in complex therapeutic areas where target validation has historically been challenging.
Posted by MedCloudInsider Editors on 02/09/20260 comments
Takeda, a Japanese pharmaceutical company, has agreed to a deal worth up to $1.7 billion with Iambic Therapeutics to expand its use of artificial intelligence in drug discovery, reinforcing a broader push to modernize early-stage research. Under the agreement, Takeda will use Iambic’s AI-driven platform to design and optimize small-molecule drug candidates, with an initial focus on multiple therapeutic targets. The structure includes upfront payments, research funding, and milestone-based fees tied to development progress. Takeda will also gain access to Iambic's NeuralPLexer model that predicts how drug molecules bind to proteins. The approach to use AI predictions fast-tracks discovery and reduces timelines, saving months of traditional lab work and creating something that could not have been done before.
The move reflects growing confidence among large pharmaceutical companies that AI can improve the speed and efficiency of drug discovery, particularly in hit identification and lead optimization. Takeda has already been active in this area, with several AI partnerships aimed at complementing internal research capabilities. For the biopharma sector, the Takeda–Iambic deal underscores how AI collaborations are shifting from experimental pilots to large, multi-target commitments. As competition intensifies, AI-driven discovery is increasingly viewed as a strategic necessity rather than a differentiator, especially for companies seeking to sustain long-term pipeline productivity.
Posted by MedCloudInsider Editors on 02/09/20260 comments
Brainomix, a global leader in AI-powered imaging, has launched a next-generation stroke AI platform called Brainomix 360 Next Generation featuring novel net water uptake technology, unveiling the system at the International Stroke Conference (ISC). The platform is designed to enhance clinicians' assessment of ischemic stroke by providing more detailed insights into brain tissue damage and edema through advanced imaging analysis. The technology helps clinicians more accurately assess tissue viability and treatment options, particularly in time-critical stroke cases.
Stroke care continues to evolve as imaging and AI tools play a larger role in guiding intervention decisions. Brainomix’s focus on net water uptake adds a quantitative layer intended to improve prediction of tissue progression and patient response. For stroke centers and healthcare systems, the platform highlights how AI-driven imaging is moving beyond detection toward deeper physiological insight, supporting more personalized and confident treatment decisions in acute stroke care.
Posted by MedCloudInsider Editors on 02/03/20260 comments